NXTC Stock Price, NextCure Inc Quote, Chart

Market Summary

USD1.37+0.08

Market Closed

6.20%

NXTC Stock Price

View Fullscreen

NXTC RSI Chart

NXTC Valuation

Market Cap

38.2M

Price/Earnings (Trailing)

-0.61

Price/Sales (Trailing)

1.81

Price/Free Cashflow

-0.71

NXTC Price/Sales (Trailing)

NXTC Profitability

Return on Equity

-54.82%

Return on Assets

-48.99%

Free Cashflow Yield

-140.72%

NXTC Fundamentals

NXTC Revenue

Revenue (TTM)

22.4M

NXTC Earnings

Earnings (TTM)

-62.7M

Earnings Growth (Yr)

16.38%

Earnings Growth (Qtr)

-1.16%

Breaking Down NXTC Revenue

Last 7 days

-14.4%

Last 30 days

-29.0%

Last 90 days

7.9%

Trailing 12 Months

-9.3%

How does NXTC drawdown profile look like?

NXTC Financial Health

Current Ratio

16.38

Debt/Equity

0.01

Debt/Cashflow

-54.5

NXTC Investor Care

Shares Dilution (1Y)

0.46%

Diluted EPS (TTM)

-2.25

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2020	27.4M	26.0M	24.4M	22.4M
2019	0	0	0	6.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of NextCure Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jul 14, 2020	heller kevin n.	acquired	48,195	1.77	27,229	chief medical officer
Nov 27, 2019	liu linda	acquired	41,656	0.754176	55,234	svp, research
Nov 15, 2019	sofinnova venture partners ix, l.p.	bought	5,512,500	36.75	150,000	-
May 13, 2019	orbimed advisors llc	acquired	-	-	2,361,010	-
May 13, 2019	orbimed advisors llc	bought	5,250,000	15.00	350,000	-
May 13, 2019	shannon timothy m	acquired	-	-	2,204,440	-
May 13, 2019	shannon timothy m	bought	750,000	15.00	50,000	-
May 13, 2019	khuong chau quang	acquired	-	-	2,361,010	-
May 13, 2019	khuong chau quang	bought	5,250,000	15.00	350,000	-
May 13, 2019	sofinnova venture partners ix, l.p.	acquired	-	-	2,121,860	-

Which funds bought or sold NXTC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 24, 2024	Assenagon Asset Management S.A.	new	-	951,579	951,579	-%
Apr 24, 2024	BML Capital Management, LLC	unchanged	-	334,047	683,417	0.45%
Mar 11, 2024	VANGUARD GROUP INC	added	0.02	-135,290	1,030,130	-%
Feb 26, 2024	Virtu Financial LLC	new	-	30,000	30,000	-%
Feb 20, 2024	Cable Car Capital LLC	new	-	702,101	702,101	0.73%
Feb 15, 2024	State of Wyoming	sold off	-100	-3,371	-	-%
Feb 15, 2024	BARCLAYS PLC	unchanged	-	-10,000	77,000	-%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-19.84	-535,052	1,300,040	-%
Feb 14, 2024	CITADEL ADVISORS LLC	reduced	-14.31	-137,338	428,469	-%
Feb 14, 2024	Royal Bank of Canada	new	-	-	-	-%

Are Funds Buying or Selling NXTC?

Are funds buying NXTC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NXTC

No. of Funds

Unveiling NextCure Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 01, 2024	logos global management lp	7.2%	2,000,460	SC 13G
Mar 08, 2024	orbimed advisors llc	4.5%	1,268,013	SC 13D/A
Jan 19, 2024	millennium management llc	4.1%	1,140,389	SC 13G/A
Feb 06, 2023	lilly asia ventures fund iii, l.p.	0%	0	SC 13G/A
Jan 24, 2023	millennium management llc	5.2%	1,449,885	SC 13G
Feb 09, 2022	lilly asia ventures fund iii, l.p.	2.1%	568,129	SC 13G/A
Jul 12, 2021	blackrock inc.	3.2%	1,204,689	SC 13G/A
May 10, 2021	morgan stanley	1.4%	399,919	SC 13G/A
Feb 16, 2021	great point partners llc	0.0%	0	SC 13G/A
Feb 12, 2021	lord, abbett & co. llc	0%	0	SC 13G/A

Recent SEC filings of NextCure Inc

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 16, 2024	PRE 14A	PRE 14A
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading

Peers (Alternatives to NextCure Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

NextCure Inc News

Latest updates

NextCure Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)								(In Thousands)
Description	(%) Q/Q	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-	-	-	-	22.00	2.00	2.00	1.00	1.00
Operating Expenses	-6.7%	16.00	17.00	16.00	14.00	14.00	11.00	10.00	8.00
S&GA Expenses	-11.3%	4.00	5.00	5.00	4.00	3.00	3.00	3.00	2.00
R&D Expenses	-5.0%	12.00	13.00	11.00	11.00	11.00	9.00	8.00	7.00
Interest Expenses	-100.0%	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Income	5.5%	-15.46	-16.37	-14.51	10.00	-10.93	-8.43	-8.22	-6.15

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-8.5%	128	140	153	168	184	190	206	223	242	258	275	291	307	316	333	343	356	205	213	145	148
Current Assets	-8.1%	113	123	135	149	164	175	193	209	228	243	259	273	288	297	315	327	340	189	197	132	136
Cash Equivalents	-33.0%	13.00	20.00	22.00	30.00	27.00	31.00	28.00	11.00	12.00	37.00	38.00	40.00	36.00	26.00	29.00	34.00	39.00	15.00	198	131	136
Net PPE	-8.2%	9.00	10.00	11.00	11.00	12.00	12.00	13.00	13.00	14.00	14.00	15.00	15.00	16.00	16.00	15.00	13.00	12.00	12.00	12.00	12.00	11.00
Liabilities	1.0%	14.00	13.00	15.00	14.00	17.00	8.00	8.00	9.00	9.00	10.00	12.00	12.00	13.00	9.00	12.00	12.00	35.00	34.00	34.00	36.00	32.00
Current Liabilities	5.1%	7.00	7.00	8.00	6.00	9.00	6.00	6.00	6.00	7.00	7.00	9.00	8.00	10.00	6.00	8.00	8.00	15.00	13.00	12.00	10.00	10.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	1.00	1.00	2.00	2.00	3.00	3.00	3.00	4.00	4.00	5.00	0.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	0.00	0.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	1.00	1.00	2.00	2.00	3.00	3.00	3.00	4.00	4.00	5.00	0.00
Shareholder's Equity	-9.5%	114	126	138	154	168	182	198	214	233	248	264	279	294	307	322	332	321	171	179	-	-
Retained Earnings	-4.7%	-324	-310	-295	-277	-261	-244	-225	-207	-187	-170	-152	-134	-117	-102	-85.81	-71.30	-81.03	-70.11	-61.67	-53.45	-47.30
Additional Paid-In Capital	0.5%	439	437	435	433	431	428	426	424	421	418	416	413	411	408	406	404	403	241	240	1.00	0.00
Shares Outstanding	0.2%	28.00	28.00	28.00	28.00	28.00	28.00	28.00	28.00	28.00	28.00	28.00	28.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	49.00	-	-	-	116	-	-	-	209	-	-	-	590	-	-	-	236	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	16.5%	-10,670	-12,778	-14,747	-14,779	-8,949	-15,001	-14,489	-15,447	-13,488	-12,662	-17,222	-13,911	-6,278	-15,673	-12,409	-10,594	-9,991	-7,947	-10,605	-7,080	22,471
Share Based Compensation	-0.8%	1,984	2,001	2,125	2,078	2,326	2,312	2,242	2,628	2,510	2,483	2,787	2,508	2,344	2,372	2,187	1,008	567	524	412	383	125
Cashflow From Investing	-59.5%	4,162	10,278	6,710	18,122	4,468	17,888	31,921	13,702	-11,001	14,414	15,588	17,600	16,498	13,103	8,549	5,373	-127,161	-174,695	-1,132	-935	-1,904
Cashflow From Financing	-	71.00	-	-	-	61.00	-	79.00	60.00	123	-2,630	-404	-354	-398	-363	-414	-240	161,308	-112	78,877	2,970	90,731

NXTC Income Statement

2023-12-31

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 47,931	$ 54,199
General and administrative	19,706	21,710
Total operating expenses	67,637	75,909
Loss from operations	(67,637)	(75,909)
Other income, net	4,914	1,176
Net loss	$ (62,723)	$ (74,733)
Net loss per common share
Basic (in dollars per share)	$ (2.25)	$ (2.69)
Diluted (in dollars per share)	$ (2.25)	$ (2.69)
Weighted average shares outstanding
Basic (in shares)	27,836,584	27,744,209
Diluted (in shares)	27,836,584	27,744,209
Comprehensive loss:
Net Income (Loss)	$ (62,723)	$ (74,733)
Unrealized gain (loss) on marketable securities	1,272	(831)
Total comprehensive loss	$ (61,451)	$ (75,564)

NXTC Balance Sheet

2023-12-31

BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 13,082	$ 26,630
Marketable securities	95,217	133,281
Prepaid expenses and other current assets	4,426	4,072
Total current assets	112,725	163,983
Property and equipment, net	9,033	11,897
Right of use assets	4,398	5,016
Other assets	1,882	3,265
Total assets	128,038	184,161
Current liabilities:
Accounts payable	2,330	4,270
Accrued liabilities and other liabilities	4,553	4,857
Total current liabilities	6,883	9,127
Lease liabilities, long term	5,949	6,605
Other long-term liabilities	785	899
Total liabilities	13,617	16,631
Stockholders' equity
Preferred stock; par value of $0.001 per share; 10,000,000 shares authorized at December 31, 2023 and December 31, 2022, No shares issued and outstanding at December 31, 2023 and December 31, 2022
Common stock, par value of $0.001 per share; 100,000,000 shares authorized at December 31, 2023 and December 31, 2022. 27,903,027 and 27,774,536 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	28	28
Additional paid-in capital	439,097	430,755
Accumulated other comprehensive loss	(222)	(1,494)
Accumulated deficit	(324,482)	(261,759)
Total stockholders' equity	114,421	167,530
Total liabilities and stockholders' equity	$ 128,038	$ 184,161

About NextCure Inc

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.

CEO	Mr. Michael S. Richman MSBA
WEBSITE	nextcure.com
INDUSTRY	Biotechnology
EMPLOYEES	99

NextCure Inc Frequently Asked Questions

What is the ticker symbol for NextCure Inc? What does NXTC stand for in stocks?

NXTC is the stock ticker symbol of NextCure Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of NextCure Inc (NXTC)?

As of Fri Apr 26 2024, market cap of NextCure Inc is 38.23 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NXTC stock?

You can check NXTC's fair value in chart for subscribers.

What is the fair value of NXTC stock?

You can check NXTC's fair value in chart for subscribers. The fair value of NextCure Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of NextCure Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NXTC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is NextCure Inc a good stock to buy?

The fair value guage provides a quick view whether NXTC is over valued or under valued. Whether NextCure Inc is cheap or expensive depends on the assumptions which impact NextCure Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NXTC.

What is NextCure Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, NXTC's PE ratio (Price to Earnings) is -0.61 and Price to Sales (PS) ratio is 1.81. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NXTC PE ratio will change depending on the future growth rate expectations of investors.